3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Neutropenia
5
Breast Neoplasms
5
Febrile Neutropenia
3
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Malignant Solid Tumors
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breastcancer
1
Breast Cancer Female
1
Interventions
Irinotecan
13
Cyclophosphamide
11
Vincristine
10
Filgrastim
10
Radiotherapy
9
Ifosfamide
9
Doxorubicin
9
Dactinomycin
7
Melphalan
6
Granulocyte Colony-Stimulating Factor
6
Etoposide
6
cixutumumab
5
Sirolimus
5
Peripheral Blood Stem Cell Transplantation
5
pegfilgrastim
4
Topotecan
4
Temozolomide
4
Radiation
4
Gemcitabine
4
Busulfan
4
temsirolimus
3
sargramostim
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
trioctyl phosphine oxide
2
regorafenib
2
olaparib
2
etoposide phosphate
2
eribulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Rhabdomyosarcoma
×
pegylated granulocyte colony-stimulating factor
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled